ASAjay Sood

Ajay Sood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ajay Sood has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Disease progression in probable limbic‐predominant age‐related TDP‐43 encephalopathy

    by Charlotte Moss, Lei Yu, Konstatinos Arfanakis, Ajay Sood, For Alzheimer'S Disease Neuroimaging Initiative

    INTRODUCTION: Limbic‐predominant age‐related transactive response DNA‐binding protein of 43 kDa (TDP‐43) encephalopathy (LATE) is confirmed in post mortem examination by TDP‐43 pathology. Applying certain criteria, we examined cognitive trajectories in probable LATE and Alzheimer's disease (AD) participants compared with cognitively normal (CN) participants. METHODS: From the Alzheimer's Disease Neuroimaging Initiative, 108 individuals were classified into AD, probable LATE, or CN groups based on cognitive status, amyloid beta/tau biomarkers, and hippocampal volume. Cognition was assessed prospectively after baseline. RESULTS: Both probable LATE and AD showed faster decline than CN participants. The magnitude of decline was generally greater in AD than in probable LATE across cognitive domains. Annual rates of change were 0.81 and 2.08 for probable LATE and AD, respectively, on the Alzheimer's Disease Assessment Scale–Cognitive Subscale, 0.24 and 0.36 on the Clinical Dementia Rating Scale–Sum of Boxes, −0.50 and −0.72 on Logical Memory II, and 5.83 and 10.98 on Trail Making Test Part B. DISCUSSION: These findings support the identification of probable LATE clinically and may inform diagnostic strategies and therapeutic trial design.

  • Open Access

    Relationship of antihypertensives with late‐life cognitive decline and neuropathology

    by Ajay Sood, Ana Werneck Capuano, Rupal Mehta, Lisa Laverne Barnes, David Alan Bennett, Zoe Arvanitakis

    INTRODUCTION: Antihypertensives (AHTs) are commonly used to treat high blood pressure and other conditions, but their associations with cognitive decline and common age‐related neuropathologies are not well understood. METHODS: More than 3300 participants from three harmonized community‐based cohorts without baseline dementia were evaluated annually for changes in cognition and > 1800 participants were analyzed for post mortem neuropathology. RESULTS: In a linear mixed effect model adjusted for age, sex, education, and race/ethnicity, AHT use was associated with higher baseline global cognition ( p < 0.001) and slower decline ( p = 0.002) in global cognition, episodic memory, and semantic memory (all p < 0.02) compared to non‐use. In the autopsy group AHT use was associated with a lower tau tangle density ( p = 0.004), but not with other neurodegenerative or cerebrovascular pathologies. These associations did not change after controlling for blood pressure or other comorbidities. DISCUSSION: AHT use is associated with slower cognitive decline and lower tau pathology in late life. Highlights: In this prospective study of > 3200 older, community‐dwelling, persons followed for a mean of 8.6 years, those who used antihypertensive (AHT) medications during the study had slower cognitive decline, especially in episodic memory and semantic memory, compared to non‐users. Among the > 1800 deceased and autopsied persons, AHT medication use was associated with fewer paired helical filament‐positive tau tangles (a marker of Alzheimer's disease) but not with other neurodegenerative or cerebrovascular pathologies, compared to non‐users. Based on observational data from a large dataset, AHT use in older persons was related to slower cognitive decline and less Alzheimer's disease pathology.


  • Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment

    by Alifiya Kapasi, Bryan David James, Lei Yu, Ajay Sood, Zoe Arvanitakis, David A. Bennett, Patricia Boyle, Julie A. Schneider

    Despite the capability of anti-amyloid monoclonal antibodies to lower β-amyloid (Aβ) brain levels, there is thus far limited clinical efficacy on cognitive outcomes. Among individuals with mild cognitive impairment (MCI) or mild-stage dementia, the cognitive impact of other brain pathologies may limit efficacy of anti-amyloid drugs. This study examined the burden and cognitive associations of mixed brain pathologies among autopsied persons who would have been considered as patients to undergo anti-amyloid treatment eligibility assessment. Eligibility was defined based on a Mini-Mental State Examination score ≥20, a clinical diagnosis of MCI or mild-stage Alzheimer dementia, and a level of Aβ pathology at autopsy indicative of having a positive amyloid PET scan (Consortium to Establish a Registry for Alzheimer's Disease score ≥moderate). The number and types of copathologies were examined. Mixed-effects models were used to examine the association of Aβ, tangles, limbic predominant age-related transactive response DNA-binding protein 43 encephalopathy neuropathologic changes (LATE-NC), infarcts, Lewy bodies (LBs), and vessel diseases, with the rate of cognitive decline. Among 428 older autopsied persons (mean age at death = 91 years, 70% women) considered for anti-amyloid treatment eligibility assessment, 58% had MCI and 42% had mild-stage Alzheimer dementia. Although the majority (94%) had a pathologic diagnosis of Alzheimer disease neuropathologic changes (ADNC), only 26% had ADNC without LATE-NC, LB, or infarcts. The majority (68%) had ADNC with ≥1 copathology with ADNC + infarcts and ADNC + LATE-NC being equally common. In mixed-effects models, tangles and arteriolosclerosis were both associated with a faster rate of global cognitive decline. Separately, tangles and LATE-NC were associated with a faster decline in episodic memory, ADNC was associated with faster decline in semantic memory with Aβ being further associated with decline in working memory, and atherosclerosis was associated with a faster decline in perceptual speed. Infarcts and LBs were not associated with decline in global cognition or any cognitive domain. Mixed pathologies are common among community-dwelling older persons considered for anti-amyloid treatment eligibility assessment. Beyond Aβ, tangles, LATE-NC, and vessel pathologies drive cognitive decline in this group of individuals, especially episodic memory decline. These findings suggest that, even among those eligible for anti-amyloid therapies, substantial cognitive decline may occur because of the presence of coexisting pathologies.


  • Open Access

    Association of late‐life cognition and brain pathology with anti‐hypertensive medications

    by Ajay Sood, Ana W. Capuano, Rupal I. Mehta, Lisa L. Barnes, David A. Bennett, Zoe Arvanitakis

    Background: Hypertension is a risk factor for cognitive impairment and dementia. Anti‐hypertensives (AHT) are commonly used in old age, but their association with cognition and brain pathology is not well understood.Method: To investigate the relation of AHT with change in cognitive function and postmortem brain pathology, we evaluated 4,207 older persons without known dementia at enrollment and a subset of 1880 participants who died and came to autopsy. Participants underwent yearly clinical evaluations that included an assessment of medications and neuropsychological testing across five cognitive domains. The participants who died underwent neuropathologic evaluation of neurodegenerative (amyloid, Lewy bodies, Tar DNA binding protein ‐43, hippocampal sclerosis) and cerebrovascular pathology (infarcts, amyloid angiopathy, atherosclerosis, or arteriosclerosis).Result: Over 3,600 participants were using AHT, of which 64% were using diuretics, 55% beta‐blockers, 50% calcium channel blockers, 44% angiotensin‐converting enzyme inhibitors, and 29% angiotensin receptor blockers any time during the study. Using a linear mixed effect model adjusted for age, sex, race and education, AHT users at study entry had a higher level (estimate = 0.106, SE = 0.025, p <0.001) and a slower decline of global cognition compared to non‐users (estimate = 0.013, SE = 0.013, p = 0.013). Analyses of cognitive domains showed a similar pattern with a higher level at study entry and a slower decline of semantic memory (estimate = 0.025, SE = 0.007, p<0.001). The use of AHT was not associated with change in other domains. In a separate analysis including only participants with neuropathology, AHT use was associated with lower tau tangle density (estimate = ‐0.20, SE = 0.07, p = 0.005) after adjusting for age at death, sex, and race. The use of AHT was not associated with other neurodegenerative pathologies or cerebrovascular pathology.Conclusion: Conclusions: AHT use in old age is associated with slower cognitive decline and fewer tau tangles in the brain. Future research will need to replicate these findings and explore underlying mechanisms by which AHTs appear to have beneficial effects on cognition.This work is supported by the following NIH grants: P30AG10161, P30AG072975, R01AG15819, R01AG17917, 5R01NS084965, 1RF1AG059621, 1RF1AG074549, R01 AG22018.

  • Open Access

    Associations of renin–angiotensin system inhibitor use with brain insulin signaling and neuropathology

    by Han Tong, Ana W. Capuano, Rupal I. Mehta, Ajay Sood, David A. Bennett, Rexford S. Ahima, Steven E. Arnold, Zoe Arvanitakis

    Objective: To examine the associations of renin–angiotensin system (RAS) inhibitor use with postmortem brain insulin signaling and neuropathology.Methods: Among Religious Orders Study participants, 150 deceased and autopsied older individuals (75 with diabetes matched to 75 without by age at death, sex, and education) had measurements of insulin receptor substrate‐1 (IRS‐1) and RAC‐alpha serine/threonine protein kinase (AKT1) collected in the prefrontal cortex using ELISA and immunohistochemistry. Alzheimer's disease (AD), brain infarcts, and cerebral vessel pathology data were assessed by systematic neuropathologic evaluations. RAS inhibitor use was determined based on visual inspection of medication containers during study visits. The associations of RAS inhibitor use with brain insulin signaling measures and neuropathology were examined using adjusted regression analyses.Results: Of the 90 RAS inhibitor users (54 with diabetes), 65 had used only angiotensin‐converting enzyme inhibitors, 11 only angiotensin II receptor blockers, and 14 used both. RAS inhibitor use was associated with lower pT308AKT1/total AKT1, but not with pS307IRS‐1/total IRS‐1 or the density of cells stained positive for pS616 IRS‐1. RAS inhibitor use was not associated with the level of global AD pathology or amyloid beta burden, but it was associated with a lower tau‐neurofibrillary tangle density. Additionally, we found a significant interaction between diabetes and RAS inhibitors on tangle density. Furthermore, AKT1 phosphorylation partially mediated the association of RAS inhibitor use with tau tangle density. Lastly, RAS inhibitor use was associated with more atherosclerosis, but not with other cerebral blood vessel pathologies or cerebral infarcts.Interpretation: Late‐life RAS inhibitor use may be associated with lower brain AKT1 phosphorylation and fewer neurofibrillary tangles.


  • Association Between Triglycerides and Risk of Dementia in Community-Dwelling Older Adults

    by Zhen Zhou, Joanne Ryan, Andrew M. Tonkin, Sophia Zoungas, Paul Lacaze, Rory Wolfe, Suzanne G. Orchard, Anne M. Murray, John J. McNeil, Chenglong Yu, et al.

    Background and Objectives: It has been suggested that higher triglyceride levels were associated with a lower risk of Alzheimer9s disease. This study aimed to examine the association of triglycerides with dementia and cognition change in community-dwelling older adults. Methods: This prospective longitudinal study used data from the ASPREE randomized trial of adults aged ≥65 years without dementia or previous cardiovascular events at enrolment. The main outcome was incident dementia. Other outcomes included changes in composite cognition and domain-specific cognition (global cognition, memory, language and executive function, and psychomotor speed). The association between baseline triglycerides and dementia risk was estimated using Cox proportional-hazard models adjusting for relevant risk factors. Linear mixed models were used to investigate cognitive change. The analysis was repeated in a sub-cohort of participants with available APOE-ε4 genetic data with additional adjustment for APOE-ε4 carrier status, and an external cohort (UK Biobank) with similar selection criteria applied. Results: The study included 18,294 ASPREE participants and 68,200 UK Biobank participants (mean age: 75.1 & 66.9 years; female: 56.3% & 52.7%; median [IQR] triglyceride:106 [80-142]mg/dl & 139 [101-193]mg/dl), with dementia recorded in 823 and 2,778 individuals over a median follow-up of 6.4 and 12.5 years, respectively. Higher triglyceride levels were associated with lower dementia risk in the entire ASPREE cohort (HR with doubling of TG: 0.82, 95% CI 0.72-0.94). Findings were similar in the sub-cohort of participants with APOE-ε4 genetic data (n=13,976), and in the UK Biobank cohort (HR was 0.82 and 0.83, respectively, all p≤0.01). Higher triglycerides were also associated with slower decline in global, composite cognition, and memory over time (p≤0.05). Discussion: Older adults with higher triglyceride levels within the normal to high-normal range had a lower dementia risk and slower cognitive decline over time compared to individuals with lower triglyceride levels. Higher triglyceride levels may be reflective of better overall health and/or lifestyle behaviors that would protect against dementia development. Future studies are warranted to investigate whether specific components within the total circulating pool of plasma triglycerides may promote better cognitive function, with the hope of informing the development of new preventive strategies.


  • Metformin, age-related cognitive decline, and brain pathology

    by Ajay Sood, Ana Werneck Capuano, Robert Smith Wilson, Lisa Laverne Barnes, Alifiya Kapasi, David Alan Bennett, Zoe Arvanitakis


  • Selective serotonin reuptake inhibitor use, age-related neuropathology and cognition in late-life

    by Ajay Sood, Robert S Wilson, Lei Yu, Tianhao Wang, Julie A Schneider, William G. Honer, David A Bennett